Recent weakness in Haleon offers buying opportunity, says Argus

Argus keeps a Buy rating and $10 price target on Haleon but notes that the recent weakness in the stock provides a buying opportunity. The company’s is leveraging its top brands that include Advil, Theraflu, and Centrum to increase household penetration and also pursuing new growth opportunities across channels and geographic regions, the analyst tells investors in a research note. Haleon also aims to take advantage of emerging secular trends, such as the growing popularity of preventive medicine, and the increasing shift from prescription to over-the-counter medications, the firm added.